Form 4: Ultragenyx Exec Trades Shares

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a transaction involving the purchase of common stock.

Summary

• Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported a transaction on July 1, 2026.
• The transaction involved the acquisition of 4,698 shares of common stock at a price of $33.13 per share.
• Following this transaction, Mr. Horn beneficially owns 100,991 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents an insider purchase, but it is executed under a pre-arranged plan and does not provide new strategic information.

Positives

• The CFO acquired shares, indicating potential confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-arranged trading strategy.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal significant strategic shifts. The purchase by a CFO can be interpreted as a positive signal, but it is important to consider the context of the Rule 10b5-1(c) plan.

Stakeholder Impact

• Shareholders: The purchase by the CFO may be viewed positively, suggesting internal confidence, but the pre-arranged nature of the trade under a 10b5-1 plan limits its predictive power.

Key Dates

Keywords

Form 4, Insider Trading, Ultragenyx Pharmaceutical, RARE, Common Stock, CFO, Beneficial Ownership